Cycloset will be featured in two poster presentations at the 73rd Scientific Sessions of the American Diabetes Association being held at McCormick Place in Chicago, Ill. from June 21 - 25, 2013.
Poster #1. The Anti-Diabetes Efficacy of Bromocriptine-QR in Type 2 Diabetes Mellitus Subjects is Enhanced Among Those with Elevated Blood Pressure and Plasma Triglyceride Levels
Poster #2 Bromocriptine-QR Attenuates the Progression to Both Cardiovascular Averse Events and Worsening Hyperglycemia in Type 2 Diabetes Mellitus Subjects in Good Glycemic Control
Solid cardiac safety.. Cycloset is currently recommended as part of medical regimen in multi-cardiac risk patients. Patent until 2032. Nice upside here.
Sentiment: Strong Buy